Etest法和Vitek 2®与肉汤微量稀释法用于新型隐球菌药敏试验的比较。

Comparison of Etests and Vitek 2 ® to broth microdilution for the susceptibility testing of Cryptococcus neoformans.

作者信息

Mahabeer Yesholata, Chang Christina C, Naidu Dianithi, Dorasamy Afton, Lewin Sharon, Ndung'u Thumbi, Moosa Mohammed-Yunus, French Martyn, Mlisana Koleka, Coovadia Yacoob

机构信息

Department of Medical Microbiology, National Health Laboratory Services, Durban, South Africa; School of Laboratory Medicine and Medical Sciences, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.

Department of Infectious Diseases, Alfred Hospital, Monash University, Melbourne, Australia; Centre of Biomedical Research, Burnet Institute, Melbourne, Australia; HIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, South Africa.

出版信息

Diagn Microbiol Infect Dis. 2014 Dec;80(4):294-8. doi: 10.1016/j.diagmicrobio.2014.09.006. Epub 2014 Sep 16.

DOI:10.1016/j.diagmicrobio.2014.09.006

PMID:25277745

Abstract

We determined the susceptibility of 102 clinical isolates Cryptococcus neoformans from Durban, South Africa, to amphotericin B, fluconazole, flucytosine, and voriconazole using broth microdilution (BMD) according to the Clinical and Laboratory Standards Institute M27-A3 document and compared these results with Etest and Vitek 2(®). Essential agreement (EA) of Etest and Vitek 2(®) compared to BMD was determined. Low MICs that were below the epidemiological cutoff values of the 4 antifungal agents tested were demonstrated by all isolates. The EA of Etests for fluconazole, amphotericin, and voriconazole was 95.1%, 83.3%, and 91.2%, respectively, and for Vitek 2(®) EA for fluconazole, amphotericin, and flucytosine was 97.1%, 95.1%, and 97.1%, respectively. The Vitek 2(®) showed good agreement with BMD and is a suitable alternative. Etests demonstrated good EA for azoles only. Clinical cryptococcal isolates from Durban remain susceptible to current recommended antifungal therapy.

摘要

我们根据临床和实验室标准协会M27 - A3文件，采用肉汤微量稀释法（BMD）测定了来自南非德班的102株新型隐球菌临床分离株对两性霉素B、氟康唑、氟胞嘧啶和伏立康唑的敏感性，并将这些结果与Etest和Vitek 2（®）进行比较。确定了Etest和Vitek 2（®）与BMD相比的基本一致性（EA）。所有分离株均显示出低于所测试的4种抗真菌药物流行病学临界值的低最低抑菌浓度（MIC）。氟康唑、两性霉素和伏立康唑的Etest的EA分别为95.1%、83.3%和91.2%，氟康唑、两性霉素和氟胞嘧啶的Vitek 2（®）的EA分别为97.1%、95.1%和97.1%。Vitek 2（®）与BMD显示出良好的一致性，是一种合适的替代方法。Etest仅显示出对唑类药物有良好的EA。来自德班的临床隐球菌分离株对目前推荐的抗真菌治疗仍敏感。